| P50 | author | Mustafa Ozen | Q70969761 |
| P2093 | author name string | Chad J Creighton | |
| | Michael Ittmann | |
| | Omer Faruk Karatas | |
| | Turhan Caskurlu | |
| | Esra Guzel | |
| | Ilknur Suer | |
| | Isin D Ekici | |
| P2860 | cites work | Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. | Q50660841 |
| | High levels of expression of human stromal cell-derived factor-1 are associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma | Q84791627 |
| | Prognostic prediction following radical prostatectomy for prostate cancer using conventional as well as molecular biological approaches | Q38047420 |
| | Current controversies in the management of biochemical failure in prostate cancer | Q38070076 |
| | MicroRNAs and human diseases: diagnostic and therapeutic potential | Q38184973 |
| | Widespread deregulation of microRNA expression in human prostate cancer. | Q38297946 |
| | Allelic imbalance at 13q14.2 approximately q14.3 in localized prostate cancer is associated with early biochemical relapse | Q38428925 |
| | Prognostic Impact of Fascin-1 Expression is More Significant in Advanced Colorectal Cancer | Q38481579 |
| | Correlation between Chemokine Receptor CXCR4 Expression and Prognostic Factors in Patients with Prostate Cancer | Q38776802 |
| | Identification of miR-133b and RB1CC1 as independent predictors for biochemical recurrence and potential therapeutic targets for prostate cancer. | Q39017152 |
| | MicroRNA profiling in lymphocytes and serum of tyrosinemia type-I patients. | Q39423877 |
| | Biochemical relapse following radical prostatectomy and miR-200a levels in prostate cancer | Q39429421 |
| | miRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression. | Q39504671 |
| | MiR-1 is a tumor suppressor in thyroid carcinogenesis targeting CCND2, CXCR4, and SDF-1alpha | Q39507329 |
| | Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells | Q39757723 |
| | Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer | Q43614751 |
| | The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer | Q24309520 |
| | Prostate cancer: 3. Individual risk factors | Q24535097 |
| | Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia | Q24539231 |
| | MicroRNAs 1, 133, and 206: critical factors of skeletal and cardiac muscle development, function, and disease | Q24608809 |
| | Statistical significance for genomewide studies | Q24681264 |
| | Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method | Q25938999 |
| | Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature | Q33993472 |
| | MicroRNA‐205–directed transcriptional activation of tumor suppressor genes in prostate cancer | Q34133056 |
| | miRNA control of tumor cell invasion and metastasis | Q34179359 |
| | miR-185 and miR-133b deregulation is associated with overall survival and metastasis in colorectal cancer. | Q34185151 |
| | microRNA-1/133a and microRNA-206/133b clusters: dysregulation and functional roles in human cancers | Q34252329 |
| | Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence | Q34991210 |
| | Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy | Q35070161 |
| | Gene expression profiling identifies clinically relevant subtypes of prostate cancer | Q35554359 |
| | MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. | Q35906143 |
| | Classifying microRNAs in cancer: the good, the bad and the ugly | Q36692737 |
| | Histone modifications as markers of cancer prognosis: a cellular view. | Q36860601 |
| | Mechanisms of Disease: biomarkers and molecular targets from microarray gene expression studies in prostate cancer | Q37024519 |
| | Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins. | Q37342007 |
| | Elevated expression of SOX2 and FGFR1 in correlation with poor prognosis in patients with small cell lung cancer | Q37349481 |
| | miR-133b, a muscle-specific microRNA, is a novel prognostic marker that participates in the progression of human colorectal cancer via regulation of CXCR4 expression | Q37400908 |
| | MicroRNAs in cancer: small molecules with a huge impact | Q37474280 |
| | The function of microRNAs, small but potent molecules, in human prostate cancer. | Q37768337 |
| | DNA methylation and miRNA expression profiling in childhood B-cell acute lymphoblastic leukemia. | Q37961789 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | e98675 | |
| P577 | publication date | 2014-06-26 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | miR-1 and miR-133b are differentially expressed in patients with recurrent prostate cancer | |
| P478 | volume | 9 | |